Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Fluorouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium Jan 18, 2014 Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer Jan 14, 2014 First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain Jan 14, 2014 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 08, 2014 New Drug Application For Naloxegol Accepted By United States Food And Drug Administration Nov 19, 2013 Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A Nov 13, 2013 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 Nov 07, 2013 Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets Oct 30, 2013 Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) Oct 24, 2013 Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day Oct 08, 2013 Pagination First page « first Previous page ‹ previous … Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Page 33 Page 34 Page 35 … Next page next › Last page last »